Roche, Prothena hus­tle to PhII with their dis­ease-mod­i­fy­ing Parkin­son's drug tar­get­ing al­pha-synu­cle­in

Prothena turned up at the big Alzheimer’s/Parkin­son’s con­fer­ence in Vi­en­na over the week­end to de­tail ear­ly-stage da­ta show­ing how its Roche-part­nered drug PRX002/RG7935 can flush out tox­ic clus­ters of al­pha-synu­cle­in in Parkin­son’s pa­tients. And they used the oc­ca­sion to note the launch of their Phase II study.

In­ves­ti­ga­tors in the Phase Ib tri­al used mul­ti­ple as­cend­ing dos­es of PRX002/RG7935 in Parkin­son’s pa­tients and found that a sin­gle dose could slash free serum al­pha-synu­cle­in lev­els by up to 97%, with the re­sponse main­tained af­ter two month­ly dos­es.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER